Christopher Heery, the Chief Medical (TASE:) Officer of Arcellx, Inc. (NASDAQ:ACLX), a $3.74 billion market cap biotech company currently trading near $69 per share, recently reported the sale of company shares totaling $581,315. According to InvestingPro analysis, the stock has declined 12.7% over the past week. The transactions were executed over two days, with a sale of 4,230 shares on January 7, 2025, at an average price of $75.53 per share, followed by a sale of 3,553 shares on January 8, 2025, at an average price of $73.69 per share. These sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Heery retains direct ownership of 25,085 shares of Arcellx common stock. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 4.29. Want deeper insights into insider trading patterns and 10+…
1
